- Q3 adjusted EPS $2.49 vs $2.09 consensus
- Revenue $18.09B vs expectations
- Keytruda IV $7.77B, Qlex $830M, combined $8.6B
Merck reported Q3 adjusted EPS of $2.49 vs $2.09 estimate, revenue $18.09B beat. Keytruda sales $8.6B beat. Raised full-year guidance midpoint. Stock rose 5% to 148.63. Comes after cancer vaccine leak caused prior drop.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.